Show simple item record

dc.contributor.authorSchramm, B
dc.contributor.authorHewison, C
dc.contributor.authorBonte, L
dc.contributor.authorJones, W
dc.contributor.authorCamélique, O
dc.contributor.authorRuangweerayut, R
dc.contributor.authorSwaddiwudhipong, W
dc.contributor.authorBonnet, M
dc.date.accessioned2012-12-11T21:06:44Z
dc.date.available2012-12-11T21:06:44Z
dc.date.issued2012-08
dc.identifier.citationJ. Clin. Microbiol 2012; 50(8): 2788-2790.en_GB
dc.identifier.issn1098-660X
dc.identifier.pmid22649015
dc.identifier.doi10.1128/JCM.01232-12
dc.identifier.urihttp://hdl.handle.net/10144/255358
dc.description.abstractSimple tuberculosis (TB) treatment monitoring tools are needed. We assessed the performance of fluorescein-diacetate (FDA) smear microscopy for detection of viable Mycobacterium tuberculosis in sputum specimens (n = 288) of TB cases under treatment compared to culture (17.4% culture positivity). FDA sensitivity was moderate (83.7% [95% confidence interval {CI}, 70.3 to 92.6]), and specificity was low (66.1% [59.5 to 72.2]). The good negative predictive value (94.8% [90.1 to 97.8]) and negative likelihood ratio (0.2) suggest using this method to rule out treatment failure in settings without access to culture.
dc.language.isoenen
dc.rightsPublished by the American Society for Microbiology - Archived on this site with kind permission from the American Society for Microbiologyen_GB
dc.subjectTuberculosisen_GB
dc.titleField evaluation of a simple fluorescence method for detection of viable Mycobacterium tuberculosis in sputum specimens during treatment follow-up.en
dc.typeArticleen
dc.contributor.departmentEpicentre, Paris, France; Médecins Sans Frontières (MSF), Paris, France;International Organization for Migration (IOM), Bangkok, Thailand; Epicentre, Geneva, Switzerlandfen_GB
dc.identifier.journalJournal of Clinical Microbiologyen_GB
refterms.dateFOA2019-03-04T10:06:29Z
html.description.abstractSimple tuberculosis (TB) treatment monitoring tools are needed. We assessed the performance of fluorescein-diacetate (FDA) smear microscopy for detection of viable Mycobacterium tuberculosis in sputum specimens (n = 288) of TB cases under treatment compared to culture (17.4% culture positivity). FDA sensitivity was moderate (83.7% [95% confidence interval {CI}, 70.3 to 92.6]), and specificity was low (66.1% [59.5 to 72.2]). The good negative predictive value (94.8% [90.1 to 97.8]) and negative likelihood ratio (0.2) suggest using this method to rule out treatment failure in settings without access to culture.


Files in this item

Thumbnail
Name:
530_Schramm et al _ FDA method_TB ...
Size:
432.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record